{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:26:07Z","timestamp":1794137167164,"version":"4.8.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"26","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Colchicine has emerged as a safe and inexpensive anti-inflammatory medication to target the residual risk of cardiovascular events in the secondary prevention of coronary artery disease. Two recently published randomized controlled trials (RCTs) investigating colchicine in the post-stroke and post-myocardial infarction (MI) populations warrant a re-evaluation of colchicine. New evidence was synthesized in a systematic review and meta-analysis to determine the long-term efficacy and safety of colchicine for the secondary prevention of vascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized controlled trials comparing the incidence of cardiovascular events between patients with clinically manifest vascular disease randomized to colchicine vs. placebo and \u226512-month follow-up were included. The primary efficacy endpoint is major adverse cardiovascular events (MACE) and includes cardiovascular mortality, MI, ischaemic stroke, and urgent coronary revascularization. The DerSimonian and Laird random effects model was used to calculate pooled effect estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six RCTs, with a pooled sample size of 21 800 patients, were included (colchicine n = 10 871; placebo n = 10 929). Over a follow-up of 12\u201334 months, colchicine reduced the incidence of MACE compared with placebo [pooled hazard ratio .75, 95% confidence interval (CI) .56\u2013.93]. The reduction in cardiovascular events among colchicine patients was driven by reductions in MIs, ischaemic strokes, and urgent coronary revascularizations (P &amp;lt; .05 for all). No differences were detected for safety outcomes (P &amp;gt; .05 for all), including non-cardiovascular deaths (risk ratio 1.08, 95% CI .76\u20131.54).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This updated meta-analysis of RCTs demonstrated a substantial reduction in MACE, MI, ischaemic stroke, and recurrent coronary revascularization with colchicine compared with placebo. Therefore, the results support the use of colchicine to reduce recurrent cardiovascular events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf174","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:21:45Z","timestamp":1741738905000},"page":"2552-2563","source":"Crossref","is-referenced-by-count":98,"title":["Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-6565","authenticated-orcid":false,"given":"Michelle","family":"Samuel","sequence":"first","affiliation":[{"name":"University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]},{"name":"Dalhousie University , Halifax ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-8636","authenticated-orcid":false,"given":"Colin","family":"Berry","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow and Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montreal, QC H1T 1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-9603","authenticated-orcid":false,"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"Technical University of Munich, School of Medicine and Health, German Heart Centre, TUM University Hospital, Munich ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance , Munich ,","place":["Germany"]},{"name":"Institute of Epidemiology and Medical Biometry, University of Ulm , Ulm ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Send\u00f3n","sequence":"additional","affiliation":[{"name":"IdiPaz Research Institute, Hospital La Paz, Universidad Autonoma de Madrid , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo Pietro","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center-Heart Care Foundation , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto J","family":"Pinto","sequence":"additional","affiliation":[{"name":"Santa Maria University Hospital, ULSSM, Center of Cardiology of the University of Lisbon, Lisbon School of Medicine, Lisbon Academic Medical Center , Lisboa ,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5288-9687","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Roubille","sequence":"additional","affiliation":[{"name":"PhyMedExp, Cardiology Department, University of Montpellier , INSERM, CNRS UMR, INI-CRT, Montpellier ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-8983","authenticated-orcid":false,"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al , 5000 Belanger Street, Montreal, QC H1T 1C8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2025070712264698800_ehaf174-B1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week","volume":"82","author":"Nelson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025070712264698800_ehaf174-B2","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week","volume":"72","author":"Libby","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025070712264698800_ehaf174-B3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"},{"key":"2025070712264698800_ehaf174-B4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"2025070712264698800_ehaf174-B5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2025070712264698800_ehaf174-B6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025070712264698800_ehaf174-B7","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2025070712264698800_ehaf174-B8","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"2025070712264698800_ehaf174-B9","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2025070712264698800_ehaf174-B10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/ehjqcco\/qcaa045","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"7","author":"Samuel","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025070712264698800_ehaf174-B11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2013update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2025070712264698800_ehaf174-B12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils","volume":"96","author":"Cronstein","year":"1995","journal-title":"J Clin Invest"},{"key":"2025070712264698800_ehaf174-B13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.cjca.2020.10.006","article-title":"Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Samuel","year":"2021","journal-title":"Can J Cardiol"},{"key":"2025070712264698800_ehaf174-B14","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025070712264698800_ehaf174-B15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"2025070712264698800_ehaf174-B16","doi-asserted-by":"publisher","first-page":"cvae191","DOI":"10.1093\/cvr\/cvae191","article-title":"Optical coherence tomography assessment of the impact of colchicine on non-culprit coronary plaque composition after myocardial infarction","author":"Psaltis","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2025070712264698800_ehaf174-B17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025070712264698800_ehaf174-B18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2025070712264698800_ehaf174-B19","doi-asserted-by":"publisher","first-page":"102835","DOI":"10.1016\/j.eclinm.2024.102835","article-title":"Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials","volume":"76","author":"Fiolet","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025070712264698800_ehaf174-B20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(24)00968-1","article-title":"Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial","volume":"404","author":"Kelly","year":"2024","journal-title":"Lancet"},{"key":"2025070712264698800_ehaf174-B21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJMc2015630","article-title":"The Covid-19 pandemic and the incidence of acute myocardial infarction","volume":"383","author":"Solomon","year":"2020","journal-title":"N Engl J Med"},{"key":"2025070712264698800_ehaf174-B22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jacc.2020.05.038","article-title":"Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic","volume":"76","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025070712264698800_ehaf174-B23","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1093\/eurheartj\/ehac374","article-title":"Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"key":"2025070712264698800_ehaf174-B24","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1056\/NEJMoa1907775","article-title":"Complete revascularization with multivessel PCI for myocardial infarction","volume":"381","author":"Mehta","year":"2019","journal-title":"N Engl J Med"},{"key":"2025070712264698800_ehaf174-B25","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"2025070712264698800_ehaf174-B26","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1093\/eurheartj\/ehac114","article-title":"The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic","volume":"43","author":"Zile","year":"2022","journal-title":"Eur Heart J"},{"key":"2025070712264698800_ehaf174-B27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/26\/2552\/63043929\/ehaf174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/26\/2552\/63043929\/ehaf174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T12:26:54Z","timestamp":1751891214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/26\/2552\/8123897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":27,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2025,5,2]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf174","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,7]]},"published":{"date-parts":[[2025,5,2]]}}}